Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

ts receiving OGX-011 plus docetaxel retreatment was 15.8 months, whereas the median survival duration for the randomized 22 patients receiving OGX-011 plus mitoxantrone arm was 11.4 months, based on a median follow-up of 26 months. An amendment to the study provided for an additional 25 patients to be treated with OGX-011 and docetaxel retreatment as second-line chemotherapy. The median survival duration for all 45 patients (i.e., the 20 randomized plus the 25 enrolled after randomization) receiving OGX-011 plus docetaxel retreatment is 13.0 months, based on a median follow-up of 18 months. For comparison, results were published for patients who participated in the key registration study comparing first-line docetaxel to mitoxantrone in metastatic CRPC, referred to as the TAX 327 Study, and who later received second-line chemotherapy. The median survival duration for these patients treated with either docetaxel or mitoxantrone as second-line chemotherapy was approximately 10 months. A retrospective study from the British Columbia Cancer Agency reported a median survival duration of 9.6 months for patients who were retreated with docetaxel as second-line chemotherapy after receiving and responding to docetaxel as first- line chemotherapy. - Non-Small Cell Lung Cancer Potential Survival Advantage - longer than expected survival duration was observed when adding OGX-011 to first- line gemcitabine and a platinum-containing chemotherapy when compared to reported survival durations in prior published studies from randomized phase 3 trials evaluating first-line gemcitabine and a platinum-containing chemotherapy in patients with non-small cell lung cancer ("NSCLC"). At two years, 30% of patients who had received OGX- 011 with first-lin
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... DUBLIN and PHILADELPHIA , June 3, ... specialty biopharmaceutical company,announces that its subsidiary Shire LLC has filed a lawsuit ... Anchen Pharmaceuticals,Inc. and Anchen, Inc. (collectively "Anchen") for the infringement of U.S.,Patent ... patent). , , , ...
... , -Proceeds to support acceleration of CYT387 Phase II myelofibrosis study- , ... MISSISSAUGA, ON , June 3 ... raised approximately US$3.2 million through a non-brokered private placement of 2,500,000 ... at no discount to the closing price of the shares on the NYSE ...
... , , , ... Endpoints , , , ... Agency in,2010 , , , ... reproductive medicine, announces positive Phase III data from its,second pivotal study (PEARL I) for its lead product ...
Cached Biology Technology:INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc. 2INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc. 3YM BioSciences raises US$3.2 million in support of JAK 1/2 program 2YM BioSciences raises US$3.2 million in support of JAK 1/2 program 3YM BioSciences raises US$3.2 million in support of JAK 1/2 program 4PregLem Announces Positive Phase III Results for Esmya(TM) 2PregLem Announces Positive Phase III Results for Esmya(TM) 3PregLem Announces Positive Phase III Results for Esmya(TM) 4
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... sectors including technology and tech stocks, releases video from the ... pickpocket and security consultant Apollo Robbins . ... about the Wocket™ biometric smart wallet, a product of NXT-ID, ...
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
(Date:1/22/2015)... Inc. , a market leader of iris-based identity authentication solutions, ... the new role of Senior Vice President of Mobile and ... platforms and wearable solutions for EyeLock,s technologies. Gerber brings more ... industry to his role at EyeLock, with expertise in human ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... PITTSBURGH, Feb. 4 Researchers at the University ... $5.6 million federal contract to pursue the continued development ... and small children with congenital or acquired heart disease. ... sophisticated technologies that have saved the lives of older ...
... that the hydrodynamic environment of fish can shape their physical ... Journal of Experimental Biology Web site, was sponsored by ... Catch a glimpse of a fish,s body shape, and you ... look as if they should outpace frilly reef fish and ...
... energy habits and provide immediate feedback on consumption could ... compromising comfort. The new energy-saving ,Wattbox, device is ... improvements supported by a 2.1 million grant from the ... As well as working with standard energy supplies, the ...
Cached Biology News:Pitt-led team gets $5.6 million contract for heart assist device for infants and toddlers 2Pitt-led team gets $5.6 million contract for heart assist device for infants and toddlers 3Research finds water movements can shape fish evolution 2Habit-learning device will lower energy bills under new clean energy cashback scheme 2